First National Trust Co Lowered By $471,796 Its Intel (INTC) Position; Syndax Pharmaceuticals (SNDX) SI Decreased By 42.29%

June 23, 2018 - By Ash

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Logo

First National Trust Co decreased Intel Corp (INTC) stake by 4.4% reported in 2018Q1 SEC filing. First National Trust Co sold 9,073 shares as Intel Corp (INTC)’s stock rose 12.89%. The First National Trust Co holds 197,253 shares with $10.27M value, down from 206,326 last quarter. Intel Corp now has $244.65 billion valuation. The stock increased 0.59% or $0.31 during the last trading session, reaching $52.5. About 32.99M shares traded or 16.32% up from the average. Intel Corporation (NASDAQ:INTC) has risen 52.90% since June 23, 2017 and is uptrending. It has outperformed by 40.33% the S&P500. Some Historical INTC News: 26/04/2018 – Intel’s diversification efforts boost revenues; 09/04/2018 – Hard OCP: Intel Rumors – Kaby Lake-X – Skylake-X and Cascade Lake; 08/05/2018 – INTEL CAPITAL – INTEL CORP’S GLOBAL INVESTMENT ORGANIZATION ANNOUNCED NEW INVESTMENTS TOTALING $72 MLN IN 12 TECHNOLOGY STARTUPS; 26/04/2018 – INTEL CORP INTC.O FY2018 SHR VIEW $3.57, REV VIEW $65.15 BLN — THOMSON REUTERS l/B/E/S; 18/04/2018 – FogHorn to Showcase lloT Edge to Cloud Machine Learning with Google and Intel at Hannover Messe 2018; 12/03/2018 – Australian Gov: WIPO PUBLISHES PATENT OF INTEL FOR “MAINTAINING A SOURCE ENB CONNECTION DURING HANDOVER” (CHINESE, AMERICAN; 26/04/2018 – Intel CEO Brian Krzanich dismissed investor concerns that functionality issues were causing 10-nanometer production delays; 17/05/2018 – MOBILEYE SAYS TO START SUPPLYING AUTOMAKER WITH SELF-DRIVING SYSTEMS STARTING IN 2021; 08/03/2018 – Pioneer Equity Income Adds Chubb, Exits Intel; 30/04/2018 – Can Blockchain Fix the Opioid Epidemic? Intel Wants to Find Out

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) had a decrease of 42.29% in short interest. SNDX’s SI was 967,500 shares in June as released by FINRA. Its down 42.29% from 1.68M shares previously. With 352,400 avg volume, 3 days are for Syndax Pharmaceuticals Inc (NASDAQ:SNDX)’s short sellers to cover SNDX’s short positions. The SI to Syndax Pharmaceuticals Inc’s float is 5.77%. The stock decreased 1.29% or $0.1 during the last trading session, reaching $7.68. About 286,374 shares traded. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has declined 29.80% since June 23, 2017 and is downtrending. It has underperformed by 42.37% the S&P500. Some Historical SNDX News: 09/04/2018 – Merck: Keytruda Monotherapy Meets Primary Endpoint in Phase 3 Study; 09/04/2018 – KEYTRUDA® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING PD; 30/04/2018 – FDA GRANTS PRIORITY REVIEW TO MERCK’S SBLA FOR KEYTRUDA®; 17/04/2018 – Dynavax Provides New Durability of Response Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Melanoma at the 2018 American Association for Cancer Research Annual Meeting; 17/05/2018 – Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab); 06/03/2018 – BIOLINERX SEES PHASE 2A BL-8040, KEYTRUDA COMBO RESULTS 2H `18; 23/04/2018 – EUROPEAN MEDICINES AGENCY VALIDATES TYPE Il VARIATION FOR MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY AS FIRST-LINE THERAPY IN METASTATIC; 10/04/2018 – BerGenBio Completes Recruitment Into First Stage of Phase Il NSCLC Trial With Selective AXL Inhibitor Bemcentinib Combined With KEYTRUDA®; 25/04/2018 – Syndax Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology Annual Meeting; 21/05/2018 – Syndax Pharmaceuticals: Elucidating The Results Of The Phase 2 ENCORE 601 Trial

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $189.74 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

More important recent Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) news were published by: Globenewswire.com which released: “Research Report Identifies NetScout, Waterstone Financial, Lindblad Expeditions, Syndax Pharmaceuticals, Hospitality …” on June 22, 2018, also Seekingalpha.com published article titled: “Syndax Pharmaceuticals: Elucidating The Results Of The Phase 2 ENCORE 601 Trial”, Seekingalpha.com published: “Syndax and Nektar Therapeutics team up in study of doublet therapy for advanced melanoma” on May 30, 2018. More interesting news about Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) was released by: Prnewswire.com and their article: “Syndax Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences” with publication date: May 30, 2018.

Analysts await Intel Corporation (NASDAQ:INTC) to report earnings on July, 26. They expect $0.86 EPS, up 19.44% or $0.14 from last year’s $0.72 per share. INTC’s profit will be $4.01 billion for 15.26 P/E if the $0.86 EPS becomes a reality. After $0.87 actual EPS reported by Intel Corporation for the previous quarter, Wall Street now forecasts -1.15% negative EPS growth.

Among 55 analysts covering Intel Corporation (NASDAQ:INTC), 36 have Buy rating, 4 Sell and 15 Hold. Therefore 65% are positive. Intel Corporation had 275 analyst reports since August 7, 2015 according to SRatingsIntel. On Friday, September 16 the stock rating was maintained by Cowen & Co with “Market Perform”. Raymond James maintained Intel Corporation (NASDAQ:INTC) on Tuesday, August 25 with “Underperform” rating. The firm has “Equal-Weight” rating by Morgan Stanley given on Friday, January 27. Deutsche Bank maintained it with “Buy” rating and $40 target in Thursday, July 21 report. The stock has “Equal-Weight” rating by Morgan Stanley on Friday, April 27. On Monday, April 30 the stock rating was maintained by Citigroup with “Buy”. The rating was maintained by Oppenheimer with “Hold” on Friday, July 28. The firm earned “Market Outperform” rating on Friday, November 20 by JMP Securities. The firm earned “Buy” rating on Thursday, April 7 by Brean Capital. The firm has “Buy” rating by FBR Capital given on Friday, April 20.

First National Trust Co increased Intl Paper Co (NYSE:IP) stake by 11,579 shares to 61,756 valued at $3.30M in 2018Q1. It also upped Praxair Inc (NYSE:PX) stake by 8,833 shares and now owns 20,260 shares. Honeywell Intl Inc (NYSE:HON) was raised too.

More notable recent Intel Corporation (NASDAQ:INTC) news were published by: Fool.com which released: “How Intel and AMD’s Partnership Could Throttle NVIDIA’s Growth” on June 23, 2018, also Fool.com with their article: “Qualcomm Isn’t Quitting Data Centers (Yet)” published on June 22, 2018, Seekingalpha.com published: “Intel Selloff, Shareholders Can Still Act” on June 19, 2018. More interesting news about Intel Corporation (NASDAQ:INTC) were released by: Seekingalpha.com and their article: “Brooks Automation: On The Up And Up” published on June 22, 2018 as well as Bizjournals.com‘s news article titled: “With Krzanich out, who’s next in line at Intel — and why succession could be difficult” with publication date: June 22, 2018.

Since January 22, 2018, it had 0 insider purchases, and 21 sales for $11.14 million activity. 1,265 Intel Corporation (NASDAQ:INTC) shares with value of $66,379 were sold by Shenoy Navin. Krzanich Brian M had sold 3,072 shares worth $144,706. 686 shares were sold by McBride Kevin Thomas, worth $31,943. HUNDT REED E had sold 20,000 shares worth $1.07M. $1.33M worth of Intel Corporation (NASDAQ:INTC) shares were sold by YOFFIE DAVID B. $1.89M worth of Intel Corporation (NASDAQ:INTC) was sold by BRYANT ANDY D on Tuesday, May 8. The insider RENDUCHINTALA VENKATA S M sold 17,946 shares worth $880,540.

Intel Corporation (NASDAQ:INTC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Ash

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: